GEN Exclusives

More »

GEN News Highlights

More »
Jul 2, 2009

Graceway Acquires Dermatological Compounds from Pfizer

  • Graceway Pharmaceuticals obtained commercialization rights to three dermatological molecules from Pfizer. The acquisition and license agreement includes related transferred or licensed intellectual properties.

    This transaction is part of Pfizer’s plan to out-license noncore programs; the firm identified CNS diseases, oncology, and cardiovascular diseases as its focus. Pfizer continues to be responsible, however, for performing developmental and clinical services for these three molecules.

    Of the acquired therapeutic candidates, two target the treatment of oily skin and acne: early-stage stearoyl CoA desaturase 1 inhibitor and Phase II cholesterol-acyltransferase (ACAT) inhibitor. The latter reportedly offers a new mechanism of action to address these common conditions and is understood to work by reducing skin surface sebum production. In addition, Graceway will acquire an activin-like kinase 5 (ALK-5) inhibitor, currently in early preclinical development for the reduction of surgical and traumatic scar formation.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Moral Calculations May Shift Biobank Balances

How should consent terms reconcile donors’ moral concerns with biobanks’ research goals?